Anti-CoV-Nucleoprotein (G7) antibody

General information on Anti-CoV-Nucleoprotein (G7) antibody

The anti-CoV-Nucleoprotein (G7) antibody was developed using the
nucleoprotein (protein N or nucleocapsid phosphoprotein) of SARS-CoV-2 as the target antigen. The fully human IgG antibody was initially discovered by screening the exclusive COVID-19 human antibody library (LiAb-SFCOVID-19™) via phage display. The antibody library, designed for a maximal abundance of anti-COVID-19 antibodies, contains the antibody repertoire of dozens of COVID-19 survivors comprising over 1010 different clones.
The nucleoprotein of the new strain of coronavirus is considered the ideal target for designing sensitive SARS-CoV-2 detection assays. This protein is one of the four main structural proteins found in the genome of SARS-CoV-2 and it plays a crucial role in RNA packaging and viral release in the post-infection stage. Nucleoprotein is not exposed on the surface of SARS-CoV-2, but it is one of the most abundantly expressed proteins during infection and proven to be highly immunogenic. Due to its exacerbated expression levels, anti-nucleoprotein antibodies are deemed useful for the detection of SARS-CoV-2 viral particles across different types of samples.
The fully human IgG anti-CoV-Nucleoprotein (G7) antibody was tested and thoroughly validated in enzyme-linked immunosorbent assay (ELISA) using recombinantly expressed nucleoprotein as the target. Moreover, the phage display-derived antibody could be easily produced in the transient mammalian system based on CHO cell lines – XtenCHO™, indicating the high stability (low aggregation potential) of the new molecule.